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Background: Suberoyl bis-hydroxamic acid (SBHA) is a histone deacetylase (HDAC) inhibitor and exerts anti-growth
effects in several malignancies including breast cancer. Proteasome inhibitors such as Bortezomib and MG-132
constitute novel anticancer agents. In this study, we investigated the synergistic antitumour activity of SBHA in
combination with proteasome inhibitors.
Methods: MCF-7 and MDA-MB-231 breast cancer cells were treated with SBHA, Bortezomib, and MG-132 alone or in
combination for 72 h. Cell proliferation, colony formation, apoptosis and gene expression changes were examined.
Results: SBHA, Bortezomib, and MG-132 alone significantly inhibited the proliferation and colony formation and induced
apoptosis in MCF-7 and MDA-MB-231 cells. Combined treatment showed a good synergistic antitumour effect against
breast cancer cells. The p53 protein level was significantly elevated by combined treatment with SBHA and proteasome
inhibitors. Moreover, combined treatment increased the expression of Bax, Bcl-xS, and Bak and decreased the expression
of Bcl-2. Combination of SBHA with proteasome inhibitors causes synergistic anticancer effects on breast cancer cells. The
potential molecular mechanism may involve induction of p53 and modulation of the Bcl-2 family proteins.
Conclusion: These findings warrant further investigation of the therapeutic benefits of combination of SBHA with
proteasome inhibitors in breast cancer.
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Breast cancer is one of the most common malignant dis-
eases affecting females worldwide, with more than 450,000
deaths each year [1]. The current treatment modalities for
breast cancer include surgical resection, adjuvant radiother-
apy, and advanced chemotherapeutic agents such as cis-
platin, pacliataxel, carboplatin, bevacizumab, doxorubicin,
cyclophosphamide, docetaxel, and epirubicin [2]. Despite
advances in treatment strategies, mortality from breast can-
cer is still high. Combination therapy is gaining increasing
attention due to increased antitumor efficacy [3,4].
Histone acetyltransferases (HATs) and histone deacety-
lases (HDACs) are known to play an opposite role in the
regulation of global gene expression via an epigenetic* Correspondence: xinmiao_yang001@163.com
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unless otherwise stated.mechanism [5]. HATs catalyze the acetylation of lysine
residues in histone tails, facilitating and sustaining gene
transcription, while HDACs are responsible for the
removal of acetyl groups from the epsilon-amine of lysine
residues of histone tails, culminating in prevention of gene
transcription. HDAC inhibitors that have the ability to
block the activities of HDACs have emerged as effective
anticancer agents [6,7]. Suberoyl bis-hydroxamic acid
(SBHA) has a similar structure to suberoylanilide hydro-
xamic acid (SAHA) and trichostatin A (TSA), two of the
mostly studied HDAC inhibitors. SBHA has been found
to exert anti-growth effects in several malignancies includ-
ing breast cancer [8].
Proteasome inhibitors such as Bortezomib and MG-132
constitute novel anticancer agents [9]. It has been sug-
gested that proteasome inhibitors interfere with the
ubiquitin-proteasome pathway that is involved in protein
turnover, likely leading to the accumulation of negativehis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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tezomib has been found to affect the expression of a large
number of genes, especially key regulators of apoptosis
such as tumor suppressor protein p53 and Bcl-2 family
proteins [10]. Preclinical studies have demonstrated the
antitumor activity of Bortezomib in breast cancer [11].
MG-132 exposure also induces cytotoxic effects on a var-
iety of cancer cells including breast cancer cells [12].
Combined treatment with HDAC inhibitors and prote-
asome inhibitors has been reported to enhance anticancer
effects compared to each reagent alone [13,14].
In this study, we aimed to check whether the combin-
ation of SBHA with proteasome inhibitors could cause
synergistic inhibitory effects on breast cancer cell growth




Two human breast cancer cell lines (MCF-7 and MDA-
MB-231) and one immortalized breast epithelial cell line
(MCF10A) were purchased from American Type Culture
Collection (ATCC, Manassas, VA, USA). Fetal bovine
serum (FBS), RPMI 1640 medium, DMEM/F-12 medium,
and TRIzol reagent were purchased from Invitrogen
(Carlsbad, CA, USA), dimethyl sulfoxide (DMSO) from
Sigma (St. Louis, MO, USA), SBHA, Bortezomib and
MG-132 from Calbiochem (San Diego, CA, USA), Cell
Counting Kit-8 (CCK-8) from Dojindo Molecular Tech-
nologies (Dojindo, Japan), First Strand cDNA synthesis kit
from Fermentas (Burlington, Canada), Annexin-FITC kit
from Beckman Coulter (Fullerton, CA, USA), and Apop-
totic DNA Ladder Kit (Beyotime, Nantong, China). Anti-
bodies anti-p53, anti-Bcl-2, anti-Bax, and anti-β-actin
were purchased from Santa Cruz Biotechnology (Santa
Cruz, CA, USA) and anti-Bak and anti-Bcl-Xs from
Calbiochem. Horseradish peroxidase-conjugated goat
anti-mouse IgG antibody was obtained from Rockland
(Gilbertsville, PA, USA).
Cell culture and treatment
MCF-7 and MDA-MB-231 cells were cultured in RPMI
1640 medium supplemented with 10% heat-inactivated FBS,
penicillin (100 units/ml), and streptomycin (100 μg/ml).
MCF10A cells were cultured in DMEM/F-12 medium con-
taining 10% FBS, 100 units/ml penicillin and 100 μg/ml
streptomycin. They were subcultured every 3-4 days.
Twenty-four hours after plating, cells were treated with
SBHA (40 μM), Bortezomib (5 nM), and MG-132 (250
nM), alone or in combination, for 72 h and then examined
for cell proliferation, apoptosis and gene expression changes.
DMSO-treated cells were used as control. To determine the
combination index (CI) for combination treatment, MCF-7
and MDA-MB-231 cells were exposed to SBHA plusBortezomib (a fixed ratio of 8000:1) or SBHA plus MG-132
(a fixed ratio of 160:1) for 72 h and cell viability was assessed
using the WST-8 assay. A series of concentrations of SBHA
were used, i.e., 10, 20, 40, and 80 μM.
WST-8 assay
The effect of SBHA on cell proliferation assays was de-
termined with the WST-8 cell proliferation assay kit.
Briefly, cells were seeded in 96-well plates at a density of
5 × 103 cells/well and incubated for 24 h. After drug
treatment, cells were incubated for further 2 h in the
presence of WST-8 reagent. The absorbance (OD) was
measured at a wavelength of 450 nm. The CI was calcu-
lated according to the classic isobologram equation [15];
CI values of 1, <1 or >1 indicate additivity, synergism or
antagonism.
Colony formation assay
MCF-7 and MDA-MB-231 cells were plated onto 6-well
plates and exposed to SBHA (40 μM), Bortezomib (5
nM), and MG-132 (250 nM), alone or in combination,
for 72 h. The cells were replated onto 6-well plates at a
density of 500 cells per well. After incubation for add-
itional 14 days, cells were washed, fixed in 10% methanol
for 15 min, and stained with Giemsa. Colonies consisting
of >50 cells were scored. Each experiment was repeated
three times.
DNA ladder assay
DNA was extracted from cells after drug treatment with
the Apoptotic DNA Ladder Kit according to the manu-
facture’s instructions. DNA samples were separated by
electrophoresis on 2% agarose gel and visualized by eth-
idium bromide staining.
Apoptosis analysis by annexin-V/PI staining
After drug treatment, cells were harvested through tryp-
sinization, washed, and centrifuged at 1,000 r/min for
5 min. The cell pellet was resuspended in 1 × binding
buffer. The cell sample solution (100 μl) was incubated
with 1 μl of fluorescein isothiocyanate (FITC)-conju-
gated annexin V and 5 μl of PI for 15 min at 4°C in the
dark. The 1 × binding buffer (400 μl) was added to each
sample tube and the samples were analyzed on a FACS-
Calibur flow cytometer using CellQuest software (BD
Biosciences, San Jose, CA, USA).
Reverse transcription-polymerase chain reaction
(RT-PCR) analysis
Total RNA was extracted from cells with TRIzol reagent
according to the manufacturer’s instructions. Comple-
mentary DNA (cDNA) was synthesized with the First-
Strand cDNA Synthesis Kit for RT-PCR. Amplification of
p53 cDNA was achieved with the following primers:
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5′-TGCAAGTCACAGACTTGGCTGT-3′ (product size,
352 bp). For loading control, glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) was amplified in a parallel
reaction, with the following primers: forward 5′-GGGAGC
CAAAAGGGTCATCATCTC-3′ and reverse 5′-CCATGC
CAGTGAGCTTCCCGTTC-3′ (product size, 353 bp). RT-
PCR products were separated by electrophoresis on 1.2%
agarose gels.
Western blot analysis
After treatment, cells were lysed in lysis buffer (10 mmol/L
Tris, pH7.4, 130 mmol/L NaCl, 1% Triton, 10 mmol/L NaF,
10 mmol/L NaPi, 10 mmol/L NaPPi, and 1.5 mmol/L
EDTA) supplemented with protease and phosphatase
inhibitors. The protein samples were separated on poly-
acrylamide gels and then transferred to a nitrocellulose
membrane. After blocking for 45 min in a Tris buffered so-
lution (TBS) containing 5% fat-free dried milk and 0.5%
Tween-20, the membrane was incubated with individual
primary antibodies overnight at 4°C. The membrane wasFigure 1 Effects of combined treatment with SBHA and proteasome inh
cells were treated with SBHA, Bortezomib, and MG-132 alone or in combinati
concentration of Bortezomib and MG-132 was 8000- and 160-fold times that
considered as 100%. *P <0.05 vs. control; #P <0.05 vs. each reagent alone. (C)
Bortezomib (5 nM), and MG-132 (250 nM), alone or in combination, for 72 h a
were numbered after 14-day incubation. Left panel: Representative dishes of
colony formation. Colony formation rate was calculated as percentage of tota
MG-132, and SBHA +MG-132 group, respectively. *P <0.05 vs. control; #P <0.05washed three times and incubated for 1 h with secondary
antibodies at room temperature. The signals were visualized
with the enhanced chemiluminescence method. Densito-
metric analysis of Western blots was performed using the
Scion Image Beta 4.02 software (SynGene, Cambridge, UK).
Statistical analysis
All data were expressed as mean ± standard deviation
(SD). Statistical significance was determined using the
Student’s t-test or one-way analysis of variance with
Tukey's post-test. P values less than 0.05 were consid-
ered statistically significant.
Results
Combination of SBHA and proteasome inhibitors inhibits
cell viability and colony formation of breast cancer cells
WST-8 assay demonstrated that SBHA treatment for
72 h significantly (P <0.05) inhibited the proliferation of
MCF-7 (Figure 1A) and MDA-MB-231 (Figure 1B) cells,
compared to control cells. When SBHA was combined
with Bortezomib, greater anti-proliferation effects wereibitors on breast cancer cell growth. (A) MCF-7 and (B) MDA-MB-231
on for 72 h and cell proliferation was assessed using the WST-8 assay. The
of SBHA, respectively. The proliferation of untreated control cells was
MCF-7 and (D) MDA-MB-231 cells were exposed to SBHA (40 μM),
nd plated onto 6-well plates at a density of 500 cells per well. Colonies
cells of each group stained with Giemsa. Right panel: Quantitation of
l seeded cells. 1-6: control, SBHA, Bortezomib, SBHA + Bortezomib,
vs. SBHA alone.
Figure 2 Effects of combined treatment with SBHA and
proteasome inhibitors on breast cancer cell apoptosis. MCF-7 cells
were exposed to SBHA (40 μM), Bortezomib (5 nM), and MG-132 (250
nM), alone or in combination, for 72 h and cell apoptosis was
examined. (A) Detection of DNA fragments via the DNA ladder assay.
Representative image of DNA fragmentation are shown. (B) MCF-7 and
(C) MDA-MB-231 cells were treated with SBHA, Bortezomib, and
MG-132 alone or in combination, and cell apoptosis was assessed by
annexin V staining assay. Results are expressed as mean ± SD of three
independent experiments. Lane 1: molecular-weight marker; lanes 2-6:
control, SBHA, Bortezomib, SBHA + Bortezomib, MG-132, and SBHA+
MG-132 group, respectively. *P <0.05 vs. control; #P <0.05 vs. each
reagent alone.
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treatment was 0.60 in MCF-7 cells and 0.57 in MDA-
MB-231 cells. The combination of SBHA with MG-132
also exerted a nearly addictive inhibitory effect on breast
cancer cell proliferation, with the CI value of 0.97 in
MCF-7 cells and 0.42 in MDA-MB-231 cells. To evalu-
ate the synergistic cytotoxicity of SBHA and proteasome
inhibitors, the non-malignant MCF10A breast epithelial
cells were treated with SBHA (40 μM), Bortezomib (5
nM), and MG-132 (250 nM), alone or in combination.
The WST-8 and LDH assays revealed that combined
SBHA and Bortezomib or MG-132 had modest adverse
effects on MCF10A cell survival (Additional file 1:
Figure S1). Therefore, the combination of SBHA with
proteasome inhibitors may yield specific inhibitory ef-
fects on cancer cells.
To further explore the effects of combination of SBHA
and proteasome inhibitors on breast cancer cell growth,
colony formation assay was done. Colonies were counted
after 14-day incubation. As illustrated in Figure 1C,
treatment with SBHA or proteasome inhibitors alone
significantly (P <0.05) decreased the colony formation of
MCF-7 cells, compared to DMSO-treated cells. Notably,
combined exposure to SBHA and Bortezomib or MG-
132 resulted in significantly greater inhibition of colony
formation (Figure 1C). Similar findings were obtained in
MDA-MB-231 cells treated with SBHA alone or in com-
bination with Bortezomib or MG-132 (Figure 1D).
Combination of SBHA and proteasome inhibitors induces
apoptosis in breast cancer cells
DNA ladder assay revealed that DNA ladder appeared in
MCF-7 cells treated with SBHA, Bortezomib, and MG-
132 alone or in combination (Figure 2A). In contrast,
DMSO-treated cells did not show typical DNA ladder.
For further quantitation of apoptosis, cells were stained
with annexin-V and PI and analyzed by flow cytometry.
As shown in Figure 2B, treatment with SBHA, Bortezo-
mib, and MG-132 alone caused a significant apoptosis in
MCF-7 cells relative to DMSO-treated cells (P <0.05).
Moreover, the combination of SBHA with Bortezomib-
or MG-132 significantly (P <0.05) enhanced apoptotic
death compared to each agent alone. Similarly, com-
bined treatment with SBHA and Bortezomib- or MG-
132 caused a significant (P <0.05) induction of apoptosis
of MDA-MB-231 cells, compared to each agent alone
(Figure 2C).
Combined exposure of MCF-7 cells to SBHA and
proteasome inhibitors upregulates p53 expression
Western blot analysis revealed that treatment with
SBHA, Bortezomib, and MG-132 alone elevated the pro-
tein level of p53 in MCF-7 cells relative to DMSO-
treated cells (Figure 3A). The p53 protein level wasfurther upregulated when SBHA was combined with
Bortezomib or MG-132. However, the p53 mRNA abun-
dance remained unchanged in each treatment group com-
pared to control (Figure 3B).
Combined treatment with SBHA and proteasome
inhibitors affects the Bcl-2 family proteins
Compared to control cells, MCF-7 cells exposed to
SBHA, Bortezomib, and MG-132 alone showed an up-
regulation of Bax, Bcl-xS, and Bak protein and downreg-
ulation of Bcl-2 protein (Figure 4). When SBHA was
Figure 3 Effects of combined treatment with SBHA and
proteasome inhibitors on p53 expression in breast cancer cells.
MCF-7 cells were exposed to SBHA (40 μM), Bortezomib (5 nM), and
MG-132 (250 nM), alone or in combination, for 72 h and p53
expression changes were examined. (A)Western blot analysis of p53
protein. Representative blots of three independent experiments with
similar results are shown. (B) Representative gel images of RT-PCR
analysis of p53 transcript are shown. Lanes 2-6: control, SBHA,
Bortezomib, SBHA + Bortezomib, MG-132, and SBHA +MG-132
group, respectively.
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of the Bcl-2 family proteins was enhanced (Figure 4).
Discussion
HDAC inhibitors have been extensively studied for their
anticancer activities. SBHA is a relatively new HDAC in-
hibitor and shows growth-suppressive effects in several
types of cancers including medullary thyroid cancer [16]
and lung cancer [17]. Zhuang et al. [8] documented that
SBHA induces p53-dependent apoptosis of MCF-7 breast
cancer cells. Our present data confirm the anticancer ef-
fects of SBHA in breast cancer cells. We found that SBHA
treatment significantly inhibited the proliferation and col-
ony formation of MCF-7 cells, compared to DMSO-
treated control cells. Similarly, treatment with proteasomeFigure 4 Effects of combined treatment with SBHA and
proteasome inhibitors on the Bcl-2 family members in breast
cancer cells. MCF-7 cells were exposed to SBHA (40 μM), Bortezomib
(5 nM), and MG-132 (250 nM), alone or in combination, for 72 h and
the Bcl-2 family proteins were examined. Western blot analysis of
indicated proteins. Representative blots of three independent experiments
with similar results are shown. Lanes 2-6: control, SBHA, Bortezomib, SBHA
+ Bortezomib, MG-132, and SBHA+MG-132 group, respectively.inhibitors also caused growth suppressive effects against
MCF-7 cells. Most interestingly, combined treatment with
SBHA and proteasome inhibitors potentiated the suppres-
sion of MCF-7 cell proliferation and colony formation.
The CI for combination of SBHA with Bortezomib was
0.60, indicating a synergism. Similar synergistic effects of
SBHA and Bortezomib were also observed in MDA-MB-
231 cells, with the IC value of 0.57. To the best of our
knowledge, this is the first report describing the synergis-
tic effects between HADC inhibitors and proteasome in-
hibitors in breast cancer. The combination of HDAC
inhibitors with Bortezomib has also been found to induce
synergistic effects against other types of cancers such as
primary effusion lymphoma [18,19].
Apoptosis is known as an active suicidal response that
plays an important role in tumor biology [20]. It is char-
acterized by cellular shrinkage without loss of plasma
membrane integrity, formation of apoptotic bodies, and
nuclear condensation and fragmentation. Maintenance
of plasma membrane integrity during apoptosis prevents
the onset of an inflammatory response that contributes
to tumor progression [21]. Therefore, specific induction
of apoptosis represents a preferred strategy for destroy-
ing tumor cells. Notably, our results demonstrated that
SBHA exposure caused a significant apoptosis in MCF-7
cells, which is consistent with the previous report [8].
Bortezomib has been documented to induce apoptosis in
breast cancer cells [22,23]. Krętowski et al. [23] reported
that Bortezomib treatment evokes a strong effect on
apoptosis in breast cancer cells in hypoxic and normoxic
conditions. In agreement with these findings, our data con-
firmed the pro-apoptotic activity of Bortezomib in breast
cancer cells. Likewise, MG-132 also showed apoptosis-
inducing activity in breast cancer cells. The combination of
SBHA with Bortezomib or MG-132 significantly induced
apoptosis of MCF-7 and MDA-MB-231 cells compared to
each reagent alone. Taken together, these findings suggest
that the synergistic anticancer activity of SBHA and prote-
asome inhibitors in breast cancer cells is, at least partially,
mediated through induction of apoptotic death. Although
combined treatment with SBHA and Bortezomib or
MG-132 caused significant cytotoxicity against breast
cancer cells, these combinations did not markedly affect
the survival of the non-malignant MCF10A breast epi-
thelial cells. Therefore, the combination of SBHA with
Bortezomib or MG-132 may yield specific inhibitory ef-
fects on cancer cells.
p53 actively promotes apoptosis and plays a key role in
controlling tumor growth [24]. We found that SBHA-
treated MCF-7 cells showed a significant elevation in the
p53 protein level, but not the p53 mRNA level, suggesting
a posttranscriptional regulation. This result is consistent
with the previous study that reported an induction of p53
expression in SBHA-treated breast cancer cells [8]. The
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proteasome pathway [24]. Proteasome inhibition leads to
stabilization of p53 [25]. As expected, MCF-7 cells had a
significant increase in the p53 protein level after exposure
to Bortezomib or MG-132. However, the mRNA abun-
dance of p53 remained unchanged in Bortezomib or MG-
132-treated cells. Most interestingly, the p53 protein level
was further elevated in MCF-7 cells with combined treat-
ment with SBHA and Bortezomib or MG-132. These find-
ings suggest that induction of p53 may represent an
important mechanism for the synergism between SBHA
and proteasome inhibitors in breast cancer; however, add-
itional direct evidence is required to confirm the involve-
ment of the p53 pathway.
p53-dependent induction of apoptosis is causally linked
to its transcriptional regulation of many target genes. Bax
is a downstream target gene of p53 and mediates p53-
dependent apoptosis. It has been documented that Bax
deficiency impairs p53-induced apoptosis in neurons [26].
The upregulation of Bax is implicated in HDAC inhibitor-
induced apoptosis in breast cancer cells [27]. For instance,
Wang et al. [27] reported that sirtinol, a class III HDAC
inhibitor, induces apoptotic death in MCF-7 cells through
upregulation of Bax. SBHA has also been documented to
enhance the expression of Bax in MCF-7 cells, which con-
tributes to p53-dependent apoptosis [8]. In agreement
with this study, our data showed that SBHA-treated
MCF-7 cells had a significant increase in the Bax protein
level. Moreover, the Bcl-xS and Bak proteins were elevated
in SBHA-treated cells. When SBHA was combined with
Bortezomib or MG-132, the upregulation of Bax, Bcl-xS,
and Bak was significantly enhanced. In contrast, the Bcl-2
protein level was deceased upon exposure to SBHA, Bor-
tezomib, and MG-132 alone or in combination. Bax is a
pro-apoptotic member of the Bcl-2 family. It undergoes
mitochondrial intramembranous homo-oligomerization in
response to apoptotic stimuli, which promotes release of
cytochrome c from mitochondria, consequently activating
the mitochondrial apoptotic pathway [28]. Bcl-xS is local-
ized in the mitochondria and induces apoptosis via activa-
tion of Bak [29]. The anti-apoptotic protein Bcl-2 is
predominantly localized to mitochondria and can interact
with Bax to inhibit its activation [30]. Taken together, our
data suggest that the pro-apoptotic activity induced by
combined treatment with SBHA and proteasome inhibi-
tors is associated with modulation of the Bcl-2 family
members.
SBHA and proteasome inhibitors have shown cytotox-
icity in a broad range of cancer types, such as colorectal
cancer [31], prostate cancer [13], and lung cancer [17].
Combination treatment with HDAC inhibitor TSA and
low-dose Bortezomib has been reported to induce syner-
gistic apoptosis in prostate cancer cells [32]. The addition
of HDAC inhibitor SAHA to Bortezomib treatment wasfound to cause synergistic effects against primary effu-
sion lymphoma cells. These studies, combined with our
present findings, suggest that apart from breast cancer,
the SBHA/proteasome inhibitor combination therapy
may induce synergistic cytotoxicity in other types of
malignancies.
In conclusion, our data demonstrate that combination
of SBHA with proteasome inhibitors enhances antican-
cer effects on breast cancer cells through promotion of
apoptotic death. Induction of p53 and modulation of the
Bcl-2 family proteins at least partially account for the
synergism between SBHA and proteasome inhibitors.
These findings warrant further investigation of the
therapeutic potential of combination of SBHA with pro-
teasome inhibitors in breast cancer.
Additional file
Additional file 1: Figure S1. Effects of combined treatment with SBHA
and proteasome inhibitors on the survival of MCF10A cells. Cells were
treated with SBHA, Bortezomib, and MG-132 alone or in combination for
72 h and cell viability and death were assessed. (A) Cell viability was
determined using the WST-8 assay. The viability of control cells was
considered as 100%. (B) LDH assay was done to assess cell death. Data
represent means ± SD of three independent experiments.
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